The Food and Drug Administration (FDA) has expanded the approval of Palynziq ® (pegvaliase-pqpz), a phenylalanine (Phe)-metabolizing enzyme, to include treatment of adolescent patients 12 years of age ...

Somapacitan, a long-acting human growth hormone analog, was evaluated in growth hormone treatment-naïve, pre-pubertal pediatric patients.

Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.

Clinical data show remibrutinib treatment leads to significant reductions in urticaria activity scores compared with placebo within the first week.

New study results presented at AAAAI 2026 show significant steroid burden in pediatric asthma patients before the initiation of biologic therapy.

Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.

Research presented at AAAAI 2026 suggests GLP-1 RAs may provide clinical benefits for asthma management in patients with excess body weight.

Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 AAAAI Annual Meeting.

Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.

A survey of Scripps Health clinicians reveals that specialty and personal risk assessment of side effects drive the chronic cough treatment gap.

Biologic therapy during pregnancy was not associated with adverse outcomes for most patients in a retrospective study presented at AAAAI 2026.

Patients with hereditary angioedema report significant unmet needs, including high costs and insurance barriers, according to data from AAAAI 2026.